The Government of Equatorial Guinea, US Energy Companies, and Sanaria Sign Agreements to Extend Support for Clinical Development of PfSPZ Vaccine for Malaria and a Pathway Towards Malaria Elimination on Bioko Island

Sanaria Inc. and the Government of Equatorial Guinea last week signed an agreement that continues their joint commitment to develop Sanaria® PfSPZ Vaccine as a tool for malaria elimination. This follows a new, broader agreement between the Government of Equatorial Guinea (EG) and industry partners, Marathon Oil Corporation, Noble Energy Inc. and Atlantic Methanol Production Company (AMPCO), to sponsor clinical development of Sanaria® PfSPZ Vaccine, including the Phase 3 clinical program starting in 2020. This long standing, successful partnership highlights the unique involvement of an African government and private-sector energy companies in developing a vaccine for a largely African problem.

Dr. Adel Mahmoud, Sanaria Board member, passes away

It is with great sadness that Sanaria shares the news of the passing of long standing Sanaria Board member, Dr. Adel Mahmoud. Dr. Mahmoud was a giant in the treatment and prevention of infectious diseases around the world. He died Monday, June 11, in New York City, age 76, from a brain hemorrhage.

Sanaria honors Ruth Nussenzweig

Ruth Nussenzweig passed away on April 1, 2018. She was a force, whose seminal findings stretching back to 1967 led to the establishment of the field of pre-erythrocytic stage malaria vaccine development and enormous progress in understanding pre-erythrocytic malaria parasite biology.

Sanaria exhibits at annual Rockville Science Day

On April 22nd Sanaria participated at the 29th annual Rockville Science Day. Our exhibit featured different stages of the mosquito life cycle and a liquid nitrogen demonstration. For many of the children it was their first time looking through a microscope. At Sanaria we strive to engage with our community and foster scientific curiosity. Check out the future scientists:|

I-PfSPZ-C meets in Senegal

The International PfSPZ Consortium (I-PfSPZ-C) held its semi-annual meeting in Dakar, Senegal on April 19, 2018. More than 40 Investigators from over 20 organizations in over 10 countries attended and presented the status and results of ongoing and recently completed, but unpublished, clinical trials of Sanaria® PfSPZ Vaccine, PfSPZ-CVac and PfSPZ Challenge worldwide.|

Sanaria’s Executive VP Process Development and Manufacturing wins Visionary Leadership Award

Frost & Sullivan’s Manufacturing Leadership (ML) Council announces the world-class manufacturing companies and individual leaders set to receive recognition as winners of the 2018 Manufacturing Leadership Awards. ML Awards winners and their partners will be honored on June 13, 2018, at a gala celebration that concludes the 14th annual Manufacturing Leadership Summit in Huntington Beach, Calif.

New film, Hope for Bioko, showcases Sanaria’s work

Fifteen years of malaria control on Bioko Island, initially by Medical Care Development International and later Sanaria Inc., represents one of the most progressive and successful Corporate Social Responsibility projects in the Global Health arena. The CSR partners in this program include Marathon Oil, Noble Energy, Equatorial Guinea Liquefied Natural Gas and Atlantic Methanol, and the important public sector financing and involvement has come from the Government of Equatorial Guinea.

International PfSPZ Consortium Annual Meeting

The International PfSPZ Consortium (I-PfSPZ-C) held its semi-annual meeting at the University of Maryland School of Medicine in Baltimore on 9th and 10th November. This meeting saw record attendance of malaria researchers associated with Sanaria's PfSPZ program with 145 attendees from 44 institutions in 14 countries present in the room and more people joining online from around the world.

Sanaria’s malaria vaccines clinical and manufacturing progress highlighted at International meetings in Baltimore

Building upon publication of clinical trial results in Nature, PNAS, Lancet Infectious Diseases, and JCI Insight in 2017, Sanaria Inc. is highlighting the work of its many collaborators at a symposium entitled “Moving Toward a PfSPZ Malaria Vaccine for Protecting Travelers and Use in Elimination Campaigns” (session 133) at the 66th meeting of the American Society of Tropical Medicine and Hygiene in Baltimore, and then at the second 2017 International PfSPZ Consortium meeting held at the University of Maryland School of Medicine.

Sanaria’s PfSPZ Vaccine Achieves Durable Protection Against Heterologous Malaria Infection in a Clinical Trial

In a report published today in the Proceedings of the National Academy of Sciences, investigators from the National Institute of Allergy and Infectious Diseases (NIAID), NIH and the University of Maryland School of Medicine reported that nine of fourteen subjects (64%) immunized with three doses of Sanaria® PfSPZ Vaccine were protected against homologous challenge with Plasmodium falciparum malaria 19 weeks after their last vaccine dose. Moreover, five of six of the protected subjects who underwent a subsequent heterologous challenge with Plasmodium falciparum 33 weeks after their last vaccine dose were protected.

Sanaria’s PfSPZ Vaccine Confers Significant Protection Against Natural Malaria infections in Mali

In a report published today in The Lancet Infectious Diseases, investigators reported that Sanaria® PfSPZ Vaccine protected against natural infections of Plasmodium falciparum, the leading cause of malaria deaths and that protection was sustained for the 24 weeks of the study in an area of intense malaria transmission.

Sanaria’s PfSPZ-CVac Vaccine Achieves High Level Protection Against Malaria in Clinical Trial

In a report published today in Nature, investigators from the University of Tübingen reported all nine subjects (100%) immunized with three doses of Sanaria® PfSPZ-CVac malaria vaccine in a recently completed clinical trial were protected against Plasmodium falciparum malaria when exposed to the disease 10 weeks after last vaccine dose. Professor Peter Kremsner, MD, Director of the Institute of Tropical Medicine at the University, led the clinical team.

Sanaria’s PfSPZ Vaccine Provides High-Level Defense Against Malaria In U.S. Navy and Army Clinical Investigation

Sanaria Inc. continues to achieve success in its coordinated efforts to develop a safe, effective and affordable vaccine that delivers mass malaria protection in humans and promotes elimination of the disease worldwide. Research published today in JCI Insight by a team of clinical investigators at the Naval Medical Research Center and Walter Reed Army Institute of Research reports that Sanaria® PfSPZ Vaccine protected against Plasmodium falciparum malaria when clinical trial participants were exposed to two strains of parasites.

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine.

Annually, malaria causes >300 million clinical cases and 1 million deaths, is responsible for the loss of >1% of gross domestic product (GDP) in Africa and is a serious concern for travelers. An effective vaccine could have a dramatic impact on the disease. For 20 years, scientists have tried to develop modern, recombinant 'subunit' malaria vaccines. This has been difficult. In fact, there is only one recombinant protein vaccine on the market for any disease, and no vaccines based on synthetic peptides, recombinant viruses, recombinant bacteria or DNA plasmids.

In memoriam: Donald ‘DA’ Henderson

Sanaria joins the international public health community in remembering Donald 'DA' Henderson after his death on August 19, 2016. Sanaria was honored to receive a visit from DA in June 2011, where after describing his relentless dedication to the eradication of Smallpox, he offered insights, advice and encouragement to Sanaria at what was a critical time in our PfSPZ Vaccine clinical development program.

Contact Us


We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Social: